

# Product Datasheet

## Bmf Antibody - BSA Free NBP1-76658

Unit Size: 0.1 mg

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

[www.novusbio.com](http://www.novusbio.com)



[technical@novusbio.com](mailto:technical@novusbio.com)

### Publications: 2

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:  
[www.novusbio.com/NBP1-76658](http://www.novusbio.com/NBP1-76658)

Updated 10/23/2024 v.20.1

Earn rewards for product  
reviews and publications.

Submit a publication at [www.novusbio.com/publications](http://www.novusbio.com/publications)

Submit a review at [www.novusbio.com/reviews/destination/NBP1-76658](http://www.novusbio.com/reviews/destination/NBP1-76658)



**NBP1-76658**

Bmf Antibody - BSA Free


Product Information	
Unit Size	0.1 mg
Concentration	1 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Peptide affinity purified
Buffer	PBS
Target Molecular Weight	22 kDa

Product Description	
Host	Rabbit
Gene ID	90427
Gene Symbol	BMF
Species	Human, Mouse
Immunogen	Antibody was raised with a synthetic peptide corresponding to 15 amino acids near the amino terminus of human Bmf. The immunogen is located within the first 50 amino acids of Bmf. Amino Acid Squence: EPSQCVVELEDDV


Product Application Details	
Applications	Western Blot, ELISA, Immunocytochemistry/ Immunofluorescence
Recommended Dilutions	Western Blot 1-2 ug/ml, ELISA 1:100-1:2000, Immunocytochemistry/ Immunofluorescence 5-10 ug/ml

**Images**


Western Blot: Bmf Antibody - BSA Free [NBP1-76658] - Bmf Antibody [NBP1-76658] - Identification of target for LPS-induced miR-29b in OCs. BMMs were incubated with M-CSF (30 ng/ml) and RANKL (40 ng/ml) for 40 h, washed thoroughly, and incubated further with LPS (50 ng/ml) in the presence of M-CSF (30 ng/ml) for 48 h. Cells were transfected with 30 nM of miR-29b mimic or con mimic in the presence of M-CSF (30 ng/ml) for 6 h. Total RNA was analyzed by qPCR to quantify the expression of BMF, PUMA, BAK1, BIM, and HRK. Expression levels with con mimic treatment were set at 1. Cell lysates were subjected to Western blot analysis with antibodies against BMF, PUMA, BAK1, BIM, HRK, and BCL-2. Antibodies against beta-actin were used for normalization. Image collected and cropped by CiteAb from the following publication (<https://www.hindawi.com/journals/omcl/2019/6018180/>) licensed under a CC-BY license.




Immunocytochemistry/Immunofluorescence: Bmf Antibody [NBP1-76658]  
- Staining of Bmf in HeLa cells with Bmf antibody at 5 ug/mL.




Western Blot: Bmf Antibody [NBP1-76658] - Analysis of Bmf in 293 cell lysate with Bmf antibody at (A) 1 and (B) 2 ug/ml.




Immunocytochemistry/Immunofluorescence: Bmf Antibody [NBP1-76658]  
- HeLa cells with Bmf antibody at 10 ug/ml.




Western Blot: Bmf Antibody - BSA Free [NBP1-76658] - Identification of target for LPS-induced miR-29b in OCs. BMMs incubated w/ M-CSF (30 ng/ml) & RANKL (40 ng/ml) for 40 h, washed thoroughly, & incubated further w/ LPS (50 ng/ml) in presence of M-CSF (30 ng/ml) for 48 h. (a) Cells transfected w/ 30 nM of miR-29b mimic or con mimic in presence of M-CSF (30 ng/ml) for 6 h. Total RNA analyzed by qPCR to quantify the expression of BMF, PUMA, BAK1, BIM, & HRK. Expression levels w/ con mimic treatment set at 1. Cell lysates subjected to WB analysis w/ antibodies against BMF, PUMA, BAK1, BIM, HRK, & BCL-2. Antibodies against  $\beta$ -actin used for normalization. (b) w/out transfection, total RNA analyzed by qPCR to quantify the expression of BMF, & cell lysates subjected to WB analysis w/ anti-BMF Ab. (c) Total RNA & tissue lysate of tibiae from LPS-treated or vehicle-treated (V, PBS) mice analyzed by qPCR to quantify the expression of BMF & subjected to WB analysis w/ antibodies against BMF. (d) Cells thoroughly washed, transfected w/ 30 nM of anti-miR-29b or con inh, & stimulated w/ LPS (50 ng/ml) in presence of M-CSF. After 48 h, total RNA analyzed by qPCR to quantify BMF expression. Expression levels w/ con inh treatment set at 1.0. Cell lysates subjected to WB analysis w/ anti-BMF & anti-BCL-2 Ab. (e) Cells thoroughly washed, transfected w/ 50 nM of scRNA or siBMF, stimulated w/ LPS (50 ng/ml) in presence of M-CSF for 48 h, & analyzed to measure TRAP-positive MNCs & annexin V-positive cells. siRNA-mediated silencing of BMF confirmed by RT-PCR & qPCR. The Ct values of genes widely distributed between 17.33 & 30.92.  $\square$   $p < 0.05$ ;  $\square\square$   $p < 0.01$ ;  $\square\square\square$   $p < 0.001$  compared w/ each corresponding control. Similar results obtained from 3 independent experiments. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/31093317>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: Bmf Antibody - BSA Free [NBP1-76658] - Identification of target for LPS-induced miR-29b in OCs. BMMs incubated w/ M-CSF (30 ng/ml) & RANKL (40 ng/ml) for 40 h, washed thoroughly, & incubated further w/ LPS (50 ng/ml) in presence of M-CSF (30 ng/ml) for 48 h. (a) Cells transfected w/ 30 nM of miR-29b mimic or con mimic in presence of M-CSF (30 ng/ml) for 6 h. Total RNA analyzed by qPCR to quantify the expression of BMF, PUMA, BAK1, BIM, & HRK. Expression levels w/ con mimic treatment set at 1. Cell lysates subjected to WB analysis w/ antibodies against BMF, PUMA, BAK1, BIM, HRK, & BCL-2. Antibodies against  $\beta$ -actin used for normalization. (b) w/out transfection, total RNA analyzed by qPCR to quantify the expression of BMF, & cell lysates subjected to WB analysis w/ anti-BMF Ab. (c) Total RNA & tissue lysate of tibiae from LPS-treated or vehicle-treated (V, PBS) mice analyzed by qPCR to quantify the expression of BMF & subjected to WB analysis w/ antibodies against BMF. (d) Cells thoroughly washed, transfected w/ 30 nM of anti-miR-29b or con inh, & stimulated w/ LPS (50 ng/ml) in presence of M-CSF. After 48 h, total RNA analyzed by qPCR to quantify BMF expression. Expression levels w/ con inh treatment set at 1.0. Cell lysates subjected to WB analysis w/ anti-BMF & anti-BCL-2 Ab. (e) Cells thoroughly washed, transfected w/ 50 nM of scRNA or siBMF, stimulated w/ LPS (50 ng/ml) in presence of M-CSF for 48 h, & analyzed to measure TRAP-positive MNCs & annexin V-positive cells. siRNA-mediated silencing of BMF confirmed by RT-PCR & qPCR. The Ct values of genes widely distributed between 17.33 & 30.92.  $\square$   $p < 0.05$ ;  $\square\square$   $p < 0.01$ ;  $\square\square\square$   $p < 0.001$  compared w/ each corresponding control. Similar results obtained from 3 independent experiments. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/31093317>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: Bmf Antibody - BSA Free [NBP1-76658] - Identification of target for LPS-induced miR-29b in OCs. BMMs incubated w/ M-CSF (30 ng/ml) & RANKL (40 ng/ml) for 40 h, washed thoroughly, & incubated further w/ LPS (50 ng/ml) in presence of M-CSF (30 ng/ml) for 48 h. (a) Cells transfected w/ 30 nM of miR-29b mimic or con mimic in presence of M-CSF (30 ng/ml) for 6 h. Total RNA analyzed by qPCR to quantify the expression of BMF, PUMA, BAK1, BIM, & HRK. Expression levels w/ con mimic treatment set at 1. Cell lysates subjected to WB analysis w/ antibodies against BMF, PUMA, BAK1, BIM, HRK, & BCL-2. Antibodies against  $\beta$ -actin used for normalization. (b) w/out transfection, total RNA analyzed by qPCR to quantify the expression of BMF, & cell lysates subjected to WB analysis w/ anti-BMF Ab. (c) Total RNA & tissue lysate of tibiae from LPS-treated or vehicle-treated (V, PBS) mice analyzed by qPCR to quantify the expression of BMF & subjected to WB analysis w/ antibodies against BMF. (d) Cells thoroughly washed, transfected w/ 30 nM of anti-miR-29b or con inh, & stimulated w/ LPS (50 ng/ml) in presence of M-CSF. After 48 h, total RNA analyzed by qPCR to quantify BMF expression. Expression levels w/ con inh treatment set at 1.0. Cell lysates subjected to WB analysis w/ anti-BMF & anti-BCL-2 Ab. (e) Cells thoroughly washed, transfected w/ 50 nM of scRNA or siBMF, stimulated w/ LPS (50 ng/ml) in presence of M-CSF for 48 h, & analyzed to measure TRAP-positive MNCs & annexin V-positive cells. siRNA-mediated silencing of BMF confirmed by RT-PCR & qPCR. The Ct values of genes widely distributed between 17.33 & 30.92. □ p < 0.05; □□ p < 0.01; □□□ p < 0.001 compared w/ each corresponding control. Similar results obtained from 3 independent experiments. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/31093317>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



## Publications

Popescu B, Stahlhut C, Tarver TC et al. Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML Cell reports. *Medicine* 2023-11-21 [PMID: 37992684]

Sul O. J, Rajasekaran M, et al. MicroRNA-29b Enhances Osteoclast Survival by Targeting BCL-2-Modifying Factor after Lipopolysaccharide Stimulation. *Oxid Med Cell Longev* 2019-05-17 [PMID: 31093317] (WB, Mouse)



### **Novus Biologicals USA**

10730 E. Briarwood Avenue  
Centennial, CO 80112  
USA  
Phone: 303.730.1950  
Toll Free: 1.888.506.6887  
Fax: 303.730.1966  
nb-customerservice@bio-techne.com

### **Bio-Techne Canada**

21 Canmotor Ave  
Toronto, ON M8Z 4E6  
Canada  
Phone: 905.827.6400  
Toll Free: 855.668.8722  
Fax: 905.827.6402  
canada.inquires@bio-techne.com

### **Bio-Techne Ltd**

19 Barton Lane  
Abingdon Science Park  
Abingdon, OX14 3NB, United Kingdom  
Phone: (44) (0) 1235 529449  
Free Phone: 0800 37 34 15  
Fax: (44) (0) 1235 533420  
info.EMEA@bio-techne.com

### **General Contact Information**

www.novusbio.com  
Technical Support: nb-technical@bio-techne.com  
Orders: nb-customerservice@bio-techne.com  
General: novus@novusbio.com

### **Products Related to NBP1-76658**

---

NBP1-76658PEP	Bmf Antibody Blocking Peptide
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

---

### **Limitations**

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit [www.novusbio.com/guarantee](http://www.novusbio.com/guarantee)

Earn gift cards/discounts by submitting a review: [www.novusbio.com/reviews/submit/NBP1-76658](http://www.novusbio.com/reviews/submit/NBP1-76658)

Earn gift cards/discounts by submitting a publication using this product:  
[www.novusbio.com/publications](http://www.novusbio.com/publications)

